Days Sales in Receivables: The average number of days it takes to collect outstanding receivable amounts from customers. Calculated as: Number of Days in Period / Receivable Turnover
Kura Oncology, Inc. (KURA) had Days Sales in Receivables of 45.71 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$17.34M |
|
$-81.00M |
|
-- |
|
$17.34M |
|
$103.60M |
|
$-86.27M |
|
$5.34M |
|
$-80.93M |
|
$-80.93M |
|
$-81.00M |
|
$-81.00M |
|
$-81.00M |
|
$-81.00M |
|
$-86.27M |
|
$-87.25M |
|
87.68M |
|
87.68M |
|
$-0.92 |
|
$-0.92 |
|
| Balance Sheet Financials | |
$708.66M |
|
$7.86M |
|
$29.70M |
|
$738.36M |
|
$116.97M |
|
$9.71M |
|
$447.25M |
|
$564.23M |
|
$174.13M |
|
$174.13M |
|
$174.13M |
|
87.86M |
|
| Cash Flow Statement Financials | |
$-64.06M |
|
$-13.10M |
|
$1.79M |
|
$224.46M |
|
$149.10M |
|
$-75.36M |
|
$37.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.06 |
|
-- |
|
-- |
|
0.05 |
|
0.06 |
|
99.67% |
|
-497.62% |
|
-497.62% |
|
-- |
|
-466.82% |
|
-467.23% |
|
$-70.70M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
1.97 |
|
|
Days Sales in Receivables |
45.71 |
-46.52% |
|
-46.52% |
|
-10.97% |
|
-44.06% |
|
$1.98 |
|
$-0.81 |
|
$-0.73 |
|